top of page
Clinical Trials
Phase 1 clinical trials of Aravax's lead product for peanut allergy, PVX108, have been successfully completed.
Phase 2 trials of PVX108 have commenced in peanut allergic adolescents and children and are now recruiting at clinics in Australia and the United States.
bottom of page